Iron oxide nanoparticle m-PEG-silane

Drug Profile

Iron oxide nanoparticle m-PEG-silane

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Industrial Technology Research Institute
  • Class Contrast media; Ferric compounds; Oxides
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Liver cancer

Most Recent Events

  • 09 Jan 2017 MegaPro Biomedical completes a phase I trial in Liver cancer (Diagnosis, In volunteers) in Taiwan (NCT02744248)
  • 01 Feb 2016 Phase-I clinical trials in Liver cancer (Diagnosis, In volunteers) in Taiwan (IV) (NCT02744248)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top